Alnylam to Host Ninth Annual “RNAi Roundtable” Webcast Series
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Kroger (KR) To Cut Corporate Workforce By About 3,000 Over 3 Years - Bloomberg
Citi Opens Upside Catalyst Watch on Alnylam Pharmaceuticals (ALNY)
September 20, 2022 5:38 AM EDTCiti analyst David Lebowitz reiterated a Buy rating and $280.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY)
Opens Upside Catalyst WatchFor an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $216.00 yesterday.
... More


